Hanmi Pharmaceutical (South Korea) announced a partnership with Chongqing Zhongfu Pharmaceutical Co., Ltd. to jointly promote amlodipine/losartan in China’s out-of-hospital market via internet channels. The collaboration expands access to the fixed-dose combination antihypertensive, originally co-developed with Merck and marketed as Amosartan (South Korea, 2009) and COZAAR XQ (international), leveraging digital platforms to drive disease awareness and patient adherence among China’s 200+ million hypertensive population.
Generic amlodipine/losartan FDCs (local Chinese pharma); Hanmi/Zhongfu differentiation via brand recognition + digital engagement
Pricing Strategy
Expected RMB 2–4 daily therapy cost – competitive with generics but premium for convenience/adherence support
Revenue Potential: Digital channel expansion targets RMB 100–200 million incremental annual sales by 2028; captures 5–8% of China FDC antihypertensive market
Physician Engagement: Digital detailing to primary care physicians; telemedicine platform partnerships for prescription initiation
Forward‑Looking Statements This brief contains forward‑looking statements regarding digital channel execution, patient acquisition rates, and market share expansion for the amlodipine/losartan partnership. Actual results may differ due to e-commerce regulatory changes, generic pricing pressure, and competitive dynamics in the China antihypertensive market.-Fineline Info & Tech
By Fineline Cube 